复星医药自研创新药复迈宁两项适应症获纳入儿童肿瘤药星光计划试点项目

复星医药
Oct 30, 2025

近日,中国国家药品监督管理局药品审评中心(CDE)官网显示,复星医药自主研发的MEK1/2抑制剂芦沃美替尼片(商品名:复迈宁®)获纳入儿童肿瘤药星光计划试点项目,适应症为朗格汉斯细胞组织细胞增生症和低级别脑胶质瘤。此次芦沃美替尼片成功纳入“星光计划”代表了药审中心对该创新药的创新性和在相关罕见肿瘤领域疗效上的认可, 同时也将提高药物的研发效率,让更多患儿早日“有药可医”。“儿童抗肿瘤药物研发鼓励...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10